Two companies aim for 2nd-gen COVID vaccines
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2066 entries already.
Entries by Thomas Gabrielczyk
Rentschler Biopharma to produce 100m doses of CureVac vaccine
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NV’s RNA-based COVID-19 vaccine candidate CVnCoV.
Italian Enthera Pharma raise €35m in Series A extension
Enthera Pharmaceuticals extends its €28m Series A financing from last July to a total of €35m as Roche Venture Fund joins the company’s investor syndicate.
German antibodies in demand in USA
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Omnix Medical bags €10.8m from EIC Accerator Fund
Israel’s Omnix Medical has been granted €10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.
Germany orders antibody therapies from USA
Germany has become the first country in Europe to buy the US emergency-approved COVID-19 antibody therapies from Regeneron and Eli Lilly.
Servier and MiNA Therapeutics sign €220m deal
French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
LSP leads €21m round into Neurent Medical
Irish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
Janssen presents one-shot COVID-19 vaccine data
J&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
Automate your DNA variant library synthesis and reduce turnaround time from weeks and months to days and hours
The BioXp system is the world’s only automated platform for on-demand DNA assembly and amplification.